Manuscript no. HAEMATOL/2012/063438 entitled “Retrospective comparison of clofarabine versus fludarabine in combination with high dose cytarabine with or without granulocyte colony-stimulating factor as salvage therapies for acute myeloid leukemia”

Authors: Pamela S. Becker, Hagop M. Kantarjian, Frederick R. Appelbaum, Barry Storer, Sherry Pierce, Jianqin Shan, Stephan Faderl, Elihu H. Estey

Information about the contributions of each person named as having participated in the study

1) Guarantor(s), i.e., person(s) who is (are) responsible for the integrity of the work as a whole:
   • Pamela S. Becker, MD, PhD, University of Washington, pbecker@u.washington.edu

According to the International Committee of Medical Journal Editors (ICMJE) (http://www.icmje.org/ethical_1author.html): “Authorship credit should be based on: 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3 …………………… Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship”.

The guarantors of this manuscript confirm that all persons designated as authors qualify for authorship, and that each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content.

2) Authors who participated in the conception of the study: Pamela Becker, Hagop Kantarjian, Frederick Appelbaum, Barry Storer, Sherry Pierce, Jianqin Shan, Stephan Faderl, Elihu Estey

3) Design & Methods. The following authors were responsible for specific investigations (please detail):
   • Pamela Becker, Frederick Appelbaum, Barry Storer and Elihu Estey were responsible for the design and methodology of the GCLAC protocol and the FHCRC analysis of data.
   • Hagop Kantarjian, Sherry Pierce, Jianqin Shan and Stephan Faderl were responsible for the fludarabine/cytarabine data and MDACC analysis of data.

4) Results. The following authors were responsible for specific portions of the results, including figures and tables (please indicate the person responsible for each figure and each table):
   • For Tables 1, 2, 3, there were contributions from Barry Storer for the FHCRC results of statistical analysis in the table and Jianqin Shan for the MDACC results of statistical analysis in the table. The remaining authors are all responsible for the content of the data reported.
   • For Figure 1, Barry Storer provided the graph representing the results of data contributed by the remainder of the authors.

5) Writing the manuscript. The following authors were responsible for writing the manuscript:
   • All authors were responsible for writing the manuscript.

6) Contributors Listed in Acknowledgments:
This work was supported by a grant from Genzyme (now Sanofi) and investigator support from the Translational Research Program of the Leukemia and Lymphoma Society (P.S.B.).